MTOR and cancer: In this specific tumor analysis, the mTOR inhibitor class of agents (via targeting AKT1 overexpression) scored the highest when compared to normal references with a Z-score of 3.7 and scored in the 96 percentile when compared to Cancer Reference Control (CRC).